Literature DB >> 20304015

Development and optimisation of a duplex real-time reverse transcription quantitative PCR assay targeting the VP7 and NS2 genes of African horse sickness virus.

M Quan1, C W Lourens, N J MacLachlan, I A Gardner, A J Guthrie.   

Abstract

Nucleotide sequences of 52 South African isolates of African horse sickness virus (AHSV) collected during 2004-2005 and including viruses of all nine AHSV serotypes, were used to design and develop a duplex real-time reverse transcription quantitative PCR (RT-PCR) assay targeting the VP7 (S8) and NS2 (S9) genes of AHSV. The assay was optimized for detection of AHSV in fresh and frozen blood of naturally infected horses. Assay performance was enhanced using random hexamers rather than gene-specific primers for RT, and with denaturation of double-stranded RNA in the presence of random hexamers. The assay was efficient with a linear range of at least five orders of magnitude. The analytical sensitivity of the assay was 132 copies of the target genes (4125 copies per ml of blood), and the assay was at least 10-fold more sensitive than virus isolation on BHK-21 cells. The assay was also highly specific because it did not detect related orbiviruses, such as bluetongue and equine encephalosis viruses. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304015     DOI: 10.1016/j.jviromet.2010.03.009

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  9 in total

1.  Umatilla virus genome sequencing and phylogenetic analysis: identification of stretch lagoon orbivirus as a new member of the Umatilla virus species.

Authors:  Manjunatha N Belaganahalli; Sushila Maan; Narender S Maan; Robert Tesh; Houssam Attoui; Peter P C Mertens
Journal:  PLoS One       Date:  2011-08-29       Impact factor: 3.240

Review 2.  Rapid molecular detection methods for arboviruses of livestock of importance to northern Europe.

Authors:  Nicholas Johnson; Katja Voller; L Paul Phipps; Karen Mansfield; Anthony R Fooks
Journal:  J Biomed Biotechnol       Date:  2011-12-15

3.  Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.

Authors:  Valeria Lulla; Aleksei Lulla; Kerstin Wernike; Andrea Aebischer; Martin Beer; Polly Roy
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

4.  Development of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification Assay for the Rapid Detection of African Horse Sickness Virus.

Authors:  V L Fowler; E L A Howson; J Flannery; M Romito; A Lubisi; M Agüero; P Mertens; C A Batten; H R Warren; J Castillo-Olivares
Journal:  Transbound Emerg Dis       Date:  2016-08-02       Impact factor: 5.005

Review 5.  African Horse Sickness: A Review of Current Understanding and Vaccine Development.

Authors:  Susan J Dennis; Ann E Meyers; Inga I Hitzeroth; Edward P Rybicki
Journal:  Viruses       Date:  2019-09-11       Impact factor: 5.048

6.  Generation of a Soluble African Horse Sickness Virus VP7 Protein Capable of Forming Core-like Particles.

Authors:  Shani Bekker; Henk Huismans; Vida van Staden
Journal:  Viruses       Date:  2022-07-26       Impact factor: 5.818

7.  Re-parameterization of a mathematical model of African horse sickness virus using data from a systematic literature search.

Authors:  Emma L Fairbanks; Marnie L Brennan; Peter P C Mertens; Michael J Tildesley; Janet M Daly
Journal:  Transbound Emerg Dis       Date:  2022-01-12       Impact factor: 4.521

8.  Real time RT-PCR assays for detection and typing of African horse sickness virus.

Authors:  Katarzyna Bachanek-Bankowska; Sushila Maan; Javier Castillo-Olivares; Nicola M Manning; Narender Singh Maan; Abraham C Potgieter; Antonello Di Nardo; Geoff Sutton; Carrie Batten; Peter P C Mertens
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

9.  Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.

Authors:  Berta Alberca; Katarzyna Bachanek-Bankowska; Marta Cabana; Eva Calvo-Pinilla; Elisenda Viaplana; Lorraine Frost; Simon Gubbins; Alicia Urniza; Peter Mertens; Javier Castillo-Olivares
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.